Press Release 1997 - Sami-Sabinsa Group | Formerly Sami Labs Limited

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sabinsa Corporation granted registered Trademark of Bacopin®

Sabinsa Corporation introduces new form of Organically bound Vanadium: Bis-Glycinatio Oxovanadium (BGOV)

Sabinsa Corporation named 7th Fastest Growing Technology company in New Jersey

Sabinsa Corporation introduces Indole-3-Carbinol

Sabinsa Corporation unit receives award from Government of India for developing Garcinia Market

About

Certificates

Global Contacts List

Get in Touch

Press Releases 1997